Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
L Ballance, R L Wilson, C C Kirwan, G Boundouki, V P Taxiarchi, B G Baker, V Rusius, M Rowland, J R Henderson, N Marikakis, J McAleer, J R Harvey, On Behalf Of The Northwest Breast Research Collaborative
BACKGROUND: Patients often ask about the time taken to return to activities of daily living (ADLs) after breast surgery, but there is a lack of data to give accurate guidance. We aimed to assess the feasibility of a study to determine the time taken to return to ADLs after mastectomy with or without breast reconstruction. MATERIALS AND METHODS: A prospective multicentre, self-reported questionnaire-based feasibility study of women who had undergone mastectomy ± reconstruction was performed, between Jan 2017 and Dec 2019...
2023: Breast Journal
#2
JOURNAL ARTICLE
Ying Jiang, Bo Wang, Jun Kang Li, Shi Yu Li, Rui Lan Niu, Nai Qin Fu, Jiao Jiao Zheng, Gang Liu, Zhi Li Wang
PURPOSE: To evaluate the prognosis of patients with benign phyllodes tumors (PTs) treated by different surgical methods and to explore the influencing factors of local recurrence. METHODS: We retrospectively analyzed 215 benign PTs from 193 patients who underwent surgery at Chinese PLA General Hospital between October 2008 and December 2020. We stratified our analysis according to surgical factors and explored the clinicopathological factors to influence local recurrence...
2023: Breast Journal
#3
JOURNAL ARTICLE
Chanjiao Yao, Lingjuan Zeng, Qin Liu, Xiaoxin Qiu, Chunyan Chen
OBJECTIVE: This study aimed to explore the roles and mechanisms of lncRNA FAM225B and PDIA4 in ovarian cancer. METHODS: RT-qPCR and Western blot assays were performed to detect the expression levels of the lncRNAs FAM225B, DDX17, and PDIA4 in the serum of patients with ovarian cancer and cell lines. Cells were transfected with lncRNA FAM225B- and PDIA4-related vectors to determine the malignant phenotypes using functional experiments. The mutual binding of lncRNA FAM225B and DDX17 was verified using RNA pull-down and RIP assays...
2023: Breast Journal
#4
JOURNAL ARTICLE
Meng Zhang, Mei Wang, Zhiming Jiang, Ziyi Fu, Jingjing Ma, Sheng Gao
Tamoxifen is a drug used for treating breast cancer (BC), especially for individuals diagnosed with estrogen receptor-positive (ER+) BC. Its prolonged use could reduce the risk of recurrence and significantly lengthen the survival rate of BC patients. However, an increasing number of patients developed resistance to tamoxifen treatment, which reduced therapeutic efficiency and caused substandard prognosis. Therefore, the exploration of the molecular processes involved in tamoxifen resistance (TR) is urgently required...
2023: Breast Journal
#5
JOURNAL ARTICLE
Khaled Abd Elaziz Ahmed Elnaghi, Hosam Ali Alghanmi, Shereef Ahmed Elsamany, Fathia Almarzoki, Mohamed Elsafty, Mohammad Jaffal
BACKGROUND: CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological factors on survival outcomes with the first-line palbociclib and hormonal therapy. Patients and Methods . In this retrospective study, we recruited patients with metastatic HR-positive and HER2-negative breast cancer...
2023: Breast Journal
#6
JOURNAL ARTICLE
Gokce Deniz Ardor, Miglena K Komforti, Helena Hanna, Onur Ibanoglu, Abigail Lochala, Aziza Nassar
INTRODUCTION: Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. Thus, HER2-low breast cancer was proposed as a separate diagnostic entity. Herein, we reclassify HER2-negative cancers according to the new HER2-low category using a modified system and further investigate HER2-very-low expression. METHODS: 114 HER2 immunohistochemistry (IHC)-negative invasive breast tumors were identified from the pathology database of Mayo Clinic, Jacksonville, FL, between January 2019 and August 2022...
2023: Breast Journal
#7
JOURNAL ARTICLE
Etienne El-Helou, Christine Eddy, Simona Picchia, Carine Van de Merckt, Magali Radermeker, Michel Moreau, Filip De Neubourg, Denis Larsimont, Isabelle Veys, C Florin Pop
INTRODUCTION: The final oncological and aesthetic results of breast-conserving surgery (BCS) are influenced by the precise localization of breast cancer (BC) tumors and by the quality of the intraoperative margin assessment technique. This study aimed to assess the effectiveness of the carbon localization (CL) technique by determining the success rate of BC identification and the proportion of adequate complete resection of BC lesions. METHODS: We conducted a cross-sectional retrospective study of patients treated with primary BCS for invasive BC who underwent CL of their BC lesion at the Jules Bordet Institute between January 2015 and December 2017...
2023: Breast Journal
#8
REVIEW
Yuanjian Fan, Ruiwan Chen, Ying Lu, Ying Lin, Yunjian Zhang, Nan Shao, Shenming Wang, Dahong Nie, Zhen Shan
BACKGROUND: Intraoperative radiotherapy (IORT) is a novel promising technology that may replace external beam radiation therapy (EBRT) as boost for patients receiving breast-conserving surgery. To better evaluate the efficacy of IORT using low-kilovoltage (low-kV) X-rays as boost, we presented this meta-analysis according to the PRISMA checklist. METHODS: Studies reported survival outcomes of intraoperative radiation using low-kilovoltage X-rays system (Intrabeam®, Carl Zeiss Meditec, Dublin, CA, USA) as boost were identified through electronic bibliographic database: PUBMED...
2023: Breast Journal
#9
REVIEW
Efthymia Skafida, Angeliki Andrikopoulou, Evangelos Terpos, Christos Markellos, Savvina Moustafa, Dimitrios Pectasides, Meletios-Athanasios Dimopoulos, Flora Zagouri, Dimitrios Vassilopoulos
BACKGROUND: Third-generation aromatase inhibitors (AIs) are the mainstay of treatment in hormone receptor (HR)-positive breast cancer. Even though it is considered to be a well-tolerated therapy, AI-induced musculoskeletal symptoms are common and may be accused for treatment discontinuation. Recently, selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors changed the therapeutic setting, and currently, ribociclib, palbociclib, and abemaciclib are all approved in combination with nonsteroidal AIs in patients with ER-positive, HER2-negative advanced or metastatic breast cancer...
2023: Breast Journal
#10
MULTICENTER STUDY
Andrea Vittorio Emanuele Lisa, Marzia Salgarello, Alessandra Huscher, Fabio Corsi, Daniele Piovani, Federica Rubbino, Stefania Andreoletti, Giovanni Papa, Francesco Klinger, Corrado Tinterri, Alberto Testori, Marta Scorsetti, Paolo Veronesi, Maria Cristina Leonardi, Mario Rietjens, Umberto Cortinovis, Valeria Summo, Emanuele Rampino Cordaro, Pier Camillo Parodi, Paolo Persichetti, Mauro Barone, Giorgio De Santis, Matteo Murolo, Michele Riccio, Angelica Aquinati, Francesco Cavaliere, Nicola Vaia, Giulia Pagura, Erica Dalla Venezia, Franco Bassetto, Vincenzo Vindigni, Luigi Ciuffreda, Maria Alessandra Bocchiotti, Alberto Sciarillo, Nadia Renzi, Graziano Meneghini, Tajna Kraljic, Andrea Loreti, Lucio Fortunato, Valentina Pino, Valeriano Vinci, Marco Klinger
PURPOSE: In modern breast cancer treatment, a growing role has been observed for breast reconstruction together with an increase in clinical indications for postmastectomy radiotherapy (PMRT). Choosing the optimum type of reconstructive technique is a clinical challenge. We therefore conducted a national multicenter study to analyze the impact of PMRT on breast reconstruction. METHODS: We conducted a retrospective case-control multicenter study on women undergoing breast reconstruction...
2023: Breast Journal
#11
JOURNAL ARTICLE
Chinmay Jani, Margaret Lotz, Sarah Keates, Yasha Gupta, Alexander Walker, Omar Al Omari, Arshi Parvez, Dipesh Patel, Maria Gnata, John Perry, Leila Khorashadi, Lisa Weissmann, Susan E Pories
Lobular neoplasia (LN) involves proliferative changes within the breast lobules. LN is divided into lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH). LCIS can be further subdivided into three subtypes: classic LCIS, pleomorphic LCIS, and LCIS with necrosis (florid type). Because classic LCIS is now considered as a benign etiology, current guidelines recommend close follow-up with imaging versus surgical excision. The goal of our study was to determine if the diagnosis of classic LN on core needle biopsy (CNB) merits surgical excision...
2023: Breast Journal
#12
JOURNAL ARTICLE
Liying Zhang, Jisen Hao, Jia Guo, Xin Zhao, Xing Yin
OBJECTIVES: To investigate the association between quantitative parameters generated using synthetic magnetic resonance imaging (SyMRI) and diffusion-weighted imaging (DWI) and Ki-67 expression level in patients with invasive ductal breast cancer (IDC). METHOD: We retrospectively reviewed the records of patients with IDC who underwent SyMRI and DWI before treatment. Precontrast and postcontrast relaxation times (T1, longitudinal; T2, transverse), proton density (PD) parameters, and apparent diffusion coefficient (ADC) values were measured in breast lesions...
2023: Breast Journal
#13
JOURNAL ARTICLE
Minghe Lv
BACKGROUND: Myosin light chain plays a vital regulatory function in a large-scale cellular physiological procedure, however, the role of myosin light chain 5 (MYL5) in breast cancer has not been reported. In this study, we aimed to elucidate the effects of MYL5 on clinical prognosis and immune cell infiltration, and further explore the potential mechanism in breast cancer patients. METHODS: In this study, we first explored the expression pattern and prognostic value of MYL5 in breast cancer across multiple databases, including Oncomine, TCGA, GTEx, GEPIA2, PrognoScan, and Kaplan-Meier Plotter...
2023: Breast Journal
#14
JOURNAL ARTICLE
Ismail Can Tercan, Baha Zengel, Ozlem Ozdemir, Demet Cavdar, Funda Tasli, Zehra Hilal Adibelli, Murat Karatas, Cenk Simsek, Isabel Raika Durusoy, Adam Uslu
OBJECTIVE: To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC). METHODS: Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC. Patients with a clinical and radiologic complete response in the axilla after NAC underwent SLNB...
2023: Breast Journal
#15
JOURNAL ARTICLE
Yik Shuen Chan, Wai Ka Hung, Lok Wa Yuen, Ho Yan Yolanda Chan, Chiu Wing Winnie Chu, Polly Suk Yee Cheung
BACKGROUND: We compared the clinico-radio-pathological characteristics of breast cancer detected through mammogram (MMG) and ultrasound (USG) and discuss the implication of the choice of imaging as the future direction of our recently launched local screening program. METHODS: Retrospective study of 14613 Hong Kong Chinese female patients with histologically confirmed breast cancer registered in the Hong Kong Breast Cancer Registry between January 2006 and February 2020...
2022: Breast Journal
#16
JOURNAL ARTICLE
Sukh Makhnoon, Angelica M Gutierrez Barrera, Roland Bassett, Aimaz Afrough, Isabelle Bedrosian, Banu K Arun
BACKGROUND: Patients with unilateral breast cancer carrying pathogenic variants in BRCA1/2 have the option to undergo contralateral prophylactic mastectomy (CPM). However, differences in CPM use and survival outcomes following CPM are poorly understood in this high-risk population, in part due to a lack of data from contemporary clinical cohorts. The objective of this study was to evaluate post-CPM overall survival (OS) and related racial/ethnic differences in a contemporary clinical cohort...
2022: Breast Journal
#17
JOURNAL ARTICLE
Jin Liu, Mingyu Gan, Zijing Lin, Qin Deng, Juan Deng, Bin Zeng, Yanling Shi, Jia Ming
BACKGROUND: Estrogen and progesterone receptor status can predict breast cancer patient prognosis and treatment sensitivity, but research on low ER and PR levels and expression balance remains limited. METHODS: From January 2010 to October 2016, 283 ER+/PR+/HER2-breast cancer patients who met the inclusion criteria were enrolled and divided into the H group (ER > 10%, N = 261) and the L group (1% ≤ ER ≤ 10%, N = 22)...
2022: Breast Journal
#18
JOURNAL ARTICLE
Leena Vehmanen, Johanna Mattson, Evangelos Karademas, Albino J Oliveira-Maia, Berta Sousa, Ruth Pat-Horenczyk, Ketti Mazzocco, Panagiotis Simos, Fátima Cardoso, Greta Pettini, Chiara Marzorati, Eleni Kolokotroni, Georgios Stamatakos, Diana Frasquilho, Paula Poikonen-Saksela
BACKGROUND: Identifying and understanding modifiable factors for the well-being of cancer patients is critical in survivorship research. We studied variables associated with the exercise habits of breast cancer patients and investigated if the achievement of exercise recommendations was associated with enhanced quality of life and/or psychological well-being. Material and Methods . 311 women from Finland, Portugal, Israel, and Italy receiving adjuvant therapy for stage I-III breast cancer answered questions about sociodemographic factors and physical exercise...
2022: Breast Journal
#19
JOURNAL ARTICLE
Varsha Harish, Zoe K Haffner, Jenna C Bekeny, Adaah A Sayyed, David H Song, Kenneth L Fan
PURPOSE: As breast-conserving procedures become increasingly safe and viable options for surgical management of breast cancer, efforts have focused on assessing and optimizing patient-reported outcome measures (PROMs), such as nipple sensation. This study aims to evaluate the current understanding of nipple-areolar complex (NAC) sensation outcomes in breast cancer patients undergoing breast cancer surgeries, namely, nipple-sparing mastectomies (NSM), skin-sparing mastectomies (SSM), and lumpectomies...
2022: Breast Journal
#20
JOURNAL ARTICLE
Yu Feng, Nan Wen, Faqing Liang, Jiao Zhou, Xiangquan Qin, Xinran Liu, Juan Li, Mengxue Qiu, Huanzuo Yang, Zhenggui Du
BACKGROUND: Endoscopic nipple- or skin-sparing mastectomy (E-N/SSM) and endoscopic latissimus dorsi muscle flap (E-LDMF) harvest have been operational difficulties over decades. The aim of this study was to describe the preliminary outcomes of our novel surgical technique, which allows the performance of E-N/SSM and E-LDMF harvest for immediate breast reconstruction (IBR) through a single cosmetic axillary incision for breast cancer patients. METHODS: This prospective study included 20 breast cancer patients who underwent E-N/SSM and E-LDMF harvesting through a single axillary incision in our hospital from September 2020 to June 2022...
2022: Breast Journal
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
